Proliferative GN | Non-proliferative GN | |||
---|---|---|---|---|
Responders (R) | Non-Responders (NR) | Responders (R) | Non-Responders (NR) | |
Patients (n) | 31 | 20 | 22 | 11 |
Uncontrolled hypertension (n) | 3 | 2 | 2 | 2 |
ACE-I or ARB treatment(n) | 29 | 18 | 21 | 11 |
Interstitium volume (%) ± SD | 30.3 ± 2.27b,c | 31.1 ± 3.11d,e | 14.2 ± 5.47b,d | 15.03 ± 7.35c,e |
Median | 22.3 | 21.5 | 16.7 | 18.3 |
Glomerulosclerosis (grade) ± SD | 1.65 ± 0.81 | 1.68 ± 0.74 | 2.66 ± 0.51 | 2.59 ± 0.61 |
Median | 1.88 | 1.99 | 2.24 | 2.15 |
Mesangial cellularity | 1.45 ± 0.28 | 1.39 ± 0.19 | 0.96 ± 0.11 | 0.87 ± 0.19 |
Median | 1.22 | 1.19 | 0.99 | 0.91 |
Serum creatinine before treatment (mg %) ± SD | 1.88 ± 1.01 | 1.86 ± 1.1 | 1.45 ± 1.19 | 1.66 ± 1.4 |
Median | 1.75 | 1.73 | 1.59 | 1.61 |
Serum creatinine after treatment (mg %) ± SD | 1.40 ± 1.42a,c | 2.17 ± 1.61 | 1.23 ± 1.14d,f | 2.39 ± 1.74 |
Median | 1.39 | 1.93 | 1.24 | 2.27 |
LDL before treatment (mg/dl) ± SD | 126 ± 41.1a,b,c | 139 ± 39.7 | 145.7 ± 39.1 | 146.8 ± 41.7 |
Median | 122.2 | 137.5 | 141.7 | 142.6 |
LDL after treatment (mg/dl) ± SD | 87.9 ± 10.4 | 88.8 ± 11.1 | 88.1 ± 9.9 | 89.5 ± 11.6 |
Median | 86.6 | 87.9 | 88.0 | 88.4 |
Total serum proteins before treatment (g/dl) ± SD | 6.02 ± 0.55 | 6.11 ± 0.58 | 5.51 ± 1.82 | 5.48 ± 1.78 |
Median | 5.88 | 5.91 | 5.55 | 5.69 |
Total serum proteins after treatment (g/dl) ± SD | 6.42 ± 0.62a,c | 5.64 ± 0.81a,d | 6.65 ± 0.6d,f | 5.24 ± 0.89c,f |
Median | 6.56 | 5.54 | 6.74 | 5.31 |
Proteins urine excretion before treatment (mg/mg Cr) ± SD | 11.4 ± 2.44b,c | 12.1 ± 6.08d,e | 61.25 ± 9.4b,d | 58.90 ± 88.18c,e |
Median | 10.5 | 11.0 | 58.5 | 51.3 |
Proteins urine excretion after treatment (mg/mg Cr) ± SD | 1.58 ± 3.1a,b,c | 2.96 ± 9.14a,e | 5.55 ± 2.25b,f | 19.9 ± 14.3b,c,e,f |
Median | 1.31 | 2.66 | 3.88 | 16.74 |